Literature DB >> 17000115

Percutaneous radiofrequency thermal ablation of primary and metastatic lung tumors.

Loukas Thanos1, Sofia Mylona, Maria Pomoni, Kalliopi Athanassiadi, Nick Theakos, Leonidas Zoganas, Nikolaos Batakis.   

Abstract

OBJECTIVE: Primary lung cancer is the leading cause of death from cancer. For patients with inoperable lung cancer, percutaneous radiofrequency thermal ablation (RFA) under CT-guidance represents a minimally invasive treatment. It can also be applied in combination with radiation therapy and chemotherapy.
MATERIALS AND METHODS: In a period of 18 months, RFA under CT-guidance 27 ablations were applied on 22 patients, 14 patients with primary lung cancer and 8 patients with metastatic lung tumor. There were 15 men and 7 women ranging in age between 48 and 79 years. All patients were not surgical candidates either due to the advanced stage or due to comorbid diseases, while five denied surgery. The lesions' size was no bigger than 6 cm (range 1-6 cm) with an average of 3.8 cm. The diagnosis of all treated lesions was obtained with percutaneous biopsy under CT guidance. The procedure was performed under local anesthesia.
RESULTS: There were no major complications observed, but a small pneumothorax and a minor hemoptysis in four cases, all conservatively treated. All patients were hospitalized for 24h. Follow-up was initially done in 1, 3, 6 and 12 months after RFA and it was accomplished by personal interview or by telephone call up to December 2005. Median progression free intervals were 26.4 months for primary lung cancer and 29.2 months for metastatic tumor.
CONCLUSION: RFA is a minimally invasive technique that can be used as a palliative treatment in nonsurgical candidates with primary or metastatic lung tumor with a low morbidity and mortality.

Entities:  

Mesh:

Year:  2006        PMID: 17000115     DOI: 10.1016/j.ejcts.2006.08.015

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  6 in total

Review 1.  Tumor ablation and nanotechnology.

Authors:  Rachel L Manthe; Susan P Foy; Nishanth Krishnamurthy; Blanka Sharma; Vinod Labhasetwar
Journal:  Mol Pharm       Date:  2010-10-07       Impact factor: 4.939

2.  CT-guided percutaneous cryoablation of central lung tumors.

Authors:  Errol Colak; Servet Tatlı; Paul B Shyn; Kemal Tuncalı; Stuart G Silverman
Journal:  Diagn Interv Radiol       Date:  2014 Jul-Aug       Impact factor: 2.630

3.  Radiofrequency ablation for lung tumors: outcomes, effects on survival, and prognostic factors.

Authors:  Okan Akhan; Ezgi Güler; Devrim Akıncı; Türkmen Çiftçi; Ilgaz Çağatay Köse
Journal:  Diagn Interv Radiol       Date:  2016 Jan-Feb       Impact factor: 2.630

4.  Techniques of interventional tumor therapy.

Authors:  Andreas H Mahnken; Philipp Bruners; Rolf W Günther
Journal:  Dtsch Arztebl Int       Date:  2008-09-19       Impact factor: 5.594

5.  Osteoid osteomas in common and in technically challenging locations treated with computed tomography-guided percutaneous radiofrequency ablation.

Authors:  Sophia Mylona; Sofia Patsoura; Panagiota Galani; Georgios Karapostolakis; Anastasia Pomoni; Loukas Thanos
Journal:  Skeletal Radiol       Date:  2010-01-12       Impact factor: 2.199

6.  Experimental study of image-guided percutaneous microwave ablation in rabbit lung VX2 tumor model.

Authors:  Xin Li; Weixing Liu; Haiyan Kou; Weihua Zhou; Tao Li; Baowei Dong; Ping Liang
Journal:  Int J Clin Exp Pathol       Date:  2014-02-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.